Loading...
13 ursodeoxycholic acid COVID-19 controlled studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Brevini (PSM) 94% 0.06 [0.00-2.37] death 0/31 14/155 Improvement, RR [CI] Treatment Control Brevini (PSM) 67% 0.33 [0.05-2.43] ventilation 1/31 15/155 Brevini (PSM) 75% 0.25 [0.03-1.79] ICU 1/31 20/155 Brevini (PSM) 40% 0.60 [0.37-0.99] hosp. 11/31 91/155 John 46% 0.54 [0.41-0.71] cases 1,607 (n) 1,607 (n) Li 40% 0.60 [0.15-2.48] hosp. 3/225 5/225 Li 29% 0.71 [0.65-0.79] hosp. time 225 (n) 225 (n) Li 80% 0.20 [0.02-1.70] severe case 1/225 5/225 Li 80% 0.20 [0.10-0.38] m/s case 10/225 50/225 Li (PSM) 11% 0.89 [0.77-0.97] cases 192/225 212/225 Yu 38% 0.62 [0.38-1.01] no recov. 62 (n) 45 (n) Liu -2% 1.02 [0.83-1.25] cases 95/146 51/80 Liu -4% 1.04 [0.90-1.20] cases 118/146 62/80 Okushin (PSM) 17% 0.83 [0.40-1.74] symp. case 10/47 12/47 Okushin (PSM) 0% 1.00 [0.57-1.76] cases 16/47 16/47 Okushin (PSM) 0% 1.00 [0.46-2.18] symp. case 10/47 10/47 Okushin (PSM) -7% 1.07 [0.60-1.90] cases 16/47 15/47 Ojeda‐Fernández -7% 1.07 [0.79-1.44] death 54/219 259/1,141 Ojeda‐Fernández 4% 0.96 [0.25-3.65] ICU 3/219 15/1,141 Ojeda‐Fernández -6% 1.06 [0.83-1.36] hosp. 77/219 393/1,141 Ojeda‐Fernández 3% 0.97 [0.81-1.16] cases n/a n/a Ojeda‐Fernández -1% 1.01 [0.81-1.27] cases 83/1,687 399/7,930 Ojeda‐Fernández 9% 0.91 [0.66-1.19] cases 43/1,125 273/6,731 Marrone -7% 1.07 [0.69-1.64] death 26/108 118/521 Ming 13% 0.87 [0.77-0.98] cases 185/3,804 297/5,060 high vs. low Gao 12% 0.88 [0.75-0.99] cases 114/163 183/230 Costello 24% 0.76 [0.53-1.08] death 7,225 (n) 4,080 (n) Costello 19% 0.81 [0.68-0.96] hosp. 7,225 (n) 4,080 (n) Costello 21% 0.79 [0.67-0.93] death/hosp. 7,225 (n) 4,080 (n) Corpechot -54% 1.54 [0.44-5.40] death 3/1,322 13/8,825 Corpechot 19% 0.81 [0.29-2.28] ICU 4/1,322 33/8,825 Corpechot 40% 0.60 [0.29-1.24] hosp. 1,322 (n) 8,825 (n) Corpechot 52% 0.48 [0.20-1.19] hosp. 6/1,322 80/8,825 Corpechot 7% 0.93 [0.26-3.29] hosp. case control Cui (PSM) 48% 0.52 [0.31-0.89] no recov. 13/64 51/131 Cui (PSM) 83% 0.17 [0.06-0.49] cases 78 (n) 137 (n) Ursodeoxycholic acid COVID-19 outcomes c19 earlyMay 2024 Favors ursodeoxycholic acid Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
